Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 17/20 | 0.59 |
| ▸ | LGALS1 | P09382 | 4/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19680866 | 1.00 | LGALS3 (0.59) | LGALS3LGALS1CA1CA2CA9 | |
| SCHEMBL19665385 | 1.00 | LGALS3 (0.59) | LGALS3LGALS1CA1CA2CA9 | |
| SCHEMBL19680865 | 1.00 | LGALS3 (0.59) | LGALS3LGALS1CA1CA2CA9 | |
| SCHEMBL19681021 | 0.95 | LGALS3 (0.60) | LGALS3LGALS1CA1CA2CA9 | |
| SCHEMBL17993259 | 0.95 | LGALS3 (0.60) | LGALS3LGALS1CA1CA2CA9 | |
| SCHEMBL19681022 | 0.95 | LGALS3 (0.60) | LGALS3LGALS1CA1CA2CA9 | |
| SCHEMBL19677756 | 0.94 | LGALS3 (0.57) | LGALS3LGALS1CA1CA2CA9 | |
| SCHEMBL23319608 | 0.91 | LGALS3 (0.55) | LGALS3LGALS1CA1CA2CA9 | |
| SCHEMBL29698553 | 0.90 | LGALS3 (0.49) | LGALS3LGALS1CA1CA2CA9 | |
| SCHEMBL19665316 | 0.89 | LGALS3 (0.49) | LGALS3LGALS1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377464-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2022-07-05 | — | — | US | disclosed |
| US-20200407391-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2020-12-31 | — | — | US | disclosed |
| US-10774102-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2020-09-15 | — | — | US | disclosed |
| US-20170349619-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407391-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS2 | LGALS3 2/4885LGALS1 1/4885CA1 667/4885 |
| US-11377464-B2 | Galactoside inhibitor of galectins | LGALS3, LGALS1, LGALS2 | LGALS3 1/4885LGALS1 2/4885CA1 463/4885 |
| US-20170349619-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | LGALS3, LGALS1, LGALS2 | LGALS3 1/4885LGALS1 2/4885CA1 503/4885 |
| US-10774102-B2 | Galactoside inhibitor of galectins | LGALS3, LGALS1, LGALS2 | LGALS3 1/4885LGALS1 2/4885CA1 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.